Key Performance
More- Earnings Score: N/A
- Momentum Score: 42
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
BioCardia Announces $4.4 Million Financing
BioCardia completed a capital raise of 3.5 million shares at $1.279 per share, extending cash runway into Q1 2027 and potentially beyond PMDA approval. The company received FDA confirmation that CardiAMP HF II trial may support premarket approval, and obtained Japan PMDA Record of Advice supporting regulatory submission for CardiAMP cell therapy for ischemic heart failure treatment.
06/08/2026, 8:00 AM • GlobeNewswire
BioCardia and FDA Align on Helix Transendocardial Delivery Catheter Clearance Pathways
BioCardia announced that the FDA identified two regulatory pathways for its Helix Transendocardial Delivery Catheter System, with the FDA's preferred route being simultaneous approval with the CardiAMP cell therapy system. The FDA raised no concerns regarding Helix safety data, device performance, or agent compatibility. An alternative DeNovo pathway was also suggested as a potential route to independent Helix market clearance.
05/08/2026, 8:00 AM • GlobeNewswire
BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026
BioCardia, Inc. announced it will hold a conference call on March 24, 2026 at 4:30 PM EDT to provide a corporate update and report financial results for the year ended December 31, 2025. The call will include management remarks followed by a Q&A session and will be available via phone and webcast.
03/19/2026, 7:47 PM • GlobeNewswire
BioCardia announced that the FDA has accepted its pre-submission package for the Helix Transendocardial Delivery Catheter, a minimally invasive device for intramyocardial therapeutic and diagnostic agent delivery. The FDA's Center for Devices and Radiological Health (CDRH) will lead the review in consultation with the Center for Biological Evaluation and Research (CBER). The company expects this approval to support its CardiAMP Cell Therapy program for treating ischemic heart failure.
03/17/2026, 6:00 AM • GlobeNewswire
BioCardia will host a conference call on November 12, 2025 at 4:30 PM EDT to discuss Q3 2025 financial results and provide a corporate update, with options for phone and webcast participation.
11/05/2025, 7:29 PM • GlobeNewswire
BioCardia's CEO Peter Altman will present a corporate update at the H. C. Wainwright conference, discussing clinical cell therapy programs, regulatory activities, and recent partnerships in cardiovascular therapeutics.
09/04/2025, 9:00 AM • GlobeNewswire
